This book provides cases and analyses of causes and consequences of difficulty in downsizing and exiting in the electronics industry during the "two lost decades" in Japan. Because of excess capacity in the industry, many electronics companies have been required for downsizing and exit since the 1990s. Exploiting corporate financial and segment datasets, it shows empirical evidence of misallocation of internal funds to "zombie" segments-intra-firm businesses suffering losses consecutively. The topics addressed in the book include the failure of Japanese corporate internal control systems, the lack of capital market pressure, employment protection, and misallocation of internal funds to businesses with few prospects. The last two decades indicate that the Japanese corporate governance systems have failed to resolve problems of excess capacity, as did US systems in the 1980s. Zombie lending is no more than one phase of the difficulty of downsizing and exit in response to excess capacity in the banking sector. Supported by both data analyses and rich anecdotal evidence, this book is highly recommended to readers who seek a convincing and comprehensive explanation of Japan's two lost decades from the points of view of difficulty in downsizing and exit. The authors' analyses have implications not only for accelerating downsizing and exit in corporate Japan, but also for the world economy.

Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

This book traces how abstract managerial ideas about maximizing production flexibility and employee freedom were translated into concrete, day-to-day practices at the Motorola plant in East Kilbride, UK. Using eyewitness accounts, the book describes how employees dealt with the increased freedom Motorola promoted amongst its employees, how employees adapted to managerial changes, specifically the elimination of large-scale management, and where the 'managerless' system came under strain. This book will be of essential reading for researchers, graduate students, and undergraduates interested in the areas of management studies, human resource management, and organizational studies, among others.

This book, originally published in 1988, reviews the development of high technology industries at global and selected national and local levels, providing a unique insight into reasons for and consequences of such modern industrial development. It appraises government policies for assisting the development of this sector and focuses on the fact that high tech industry tends to be concentrated in particular regions of countries which attain the status of 'successful populations'. High technology industry seems to offer little benefit to declining manufacturing areas and the book offers explanations for these regional concentrations and assesses the likely consequences.

Originally published in 1988, this book explores how new technologies, industrial innovation and the growth of high technology industry have affected regional employment and economic change in different European countries. It discusses the factors which make some areas better suited than others to the development of the new industries, emphasising how fuctional integration and dependence upon highly-qualified manpower tend to concentrate these industries in particular locations. Attempts to encourage innovation and the development of high technology industry in old industrial areas are discussed, with particular reference to the role of large firms, training programmes and government policies.

The influence of European Competition Law is global, and Competition Law and Regulation of Technology Markets takes a practical, integrated approach to competition law, which is becoming increasingly prominent in the technology sector in Europe - as demonstrated by a number of high profile cases such as Microsoft, Sony/BMG and Intel.
The book focuses on the information, communication and media markets that form the 'new economy'. It provides a coherent analysis of these various markets by considering the regulatory context, and by addressing the issues, and ensuing legal problems, that are common to them. These include; high fixed costs, the importance of intellectual property and standards, the impact of interoperability, and the prevalence of the network effect.
The book considers how EU competition rules interact with regulation, intellectual property law and data protection rules, and goes on to analyze the application of competition rules in four fields; communications networks, industrial intellectual property, creative intellectual property, and electronic commerce and services.. The book charts a clear path through this complex interaction of rules, and provides the competition law practitioner with the necessary tools to advise on legal problems in these sectors.

High-tech businesses form a crucial part of entrepreneurial activity in some ways representing very typical examples of entrepreneurship, yet in some ways representing quite different challenges. The uncertainty in innovation and advanced technology makes it difficult to use conventional economic planning models, and also means that the management skills used in this area must be more responsive to issues of risk, uncertainty and evaluation than in conventional business opportunities.
While entrepreneurial courses do reflect the importance of high-tech businesses, they often lack the resources needed to teach this in a way that goes beyond standard how to start up a business courses whilst not focusing solely on theoretical models. This book specifically focuses on the mix of theory and practice needed to accurately inform students. Key topics covered include:
* uncertainty and innovation
* entrepreneurial finance
* marketing technological innovations
* high-tech incubation management.
Including case studies to give practical insights into genuine business examples, this comprehensive book has a distinctly real-world focus throughout. Edited by a multi-national team, it draws together leading writers and researchers from across Europe, and is therefore a must-read for all those involved in advanced entrepreneurship with specific interests in high-tech start-ups.

Transform your research into commercial biomedical products with this revised and updated second edition. Covering drugs, devices and diagnostics, this book provides a step-by-step introduction to the process of commercialization, and will allow you to create a realistic business plan to develop your ideas into approved biomedical technologies. This new edition includes: Over 25% new material, including practical tips on startup creation from experienced entrepreneurs. Tools for starting, growing and managing a new venture, including business planning and commercial strategy, pitching investors, and managing operations. Global real-world case studies, including emerging technologies such as regulated medical software and Artificial Intelligence (AI), offer insights into key challenges and help illustrate complex points. Tips and operational tools from established industry insiders, suitable for graduate students and new biomedical entrepreneurs.

"Free as in Freedom" interweaves biographical snapshots of GNU project founder Richard Stallman with the political, social and economic history of the free software movement. It examines Stallman's unique personality and how that personality has been at turns a driving force and a drawback in terms of the movement's overall success.

"Free as in Freedom" examines one man's 20-year attempt to codify and communicate the ethics of 1970s era "hacking" culture in such a way that later generations might easily share and build upon the knowledge of their computing forebears. The book documents Stallman's personal evolution from teenage misfit to prescient adult hacker to political leader and examines how that evolution has shaped the free software movement. Like Alan Greenspan in the financial sector, Richard Stallman has assumed the role of tribal elder within the hacking community, a community that bills itself as anarchic and averse to central leadership or authority. How did this paradox come about? "Free as in Freedom" provides an answer. It also looks at how the latest twists and turns in the software marketplace have diminished Stallman's leadership role in some areas while augmenting it in others.

Finally, "Free as in Freedom" examines both Stallman and the free software movement from historical viewpoint. Will future generations see Stallman as a genius or crackpot? The answer to that question depends partly on which side of the free software debate the reader currently stands and partly upon the reader's own outlook for the future. 100 years from now, when terms such as "computer," "operating system" and perhaps even "software" itself seem hopelessly quaint, will Richard Stallman's particular vision of freedom still resonate, or will it have taken its place alongside other utopian concepts on the 'ash-heap of history?'

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

A New York Times bestseller.

Winner of the Financial Times/McKinsey Business Book of the Year Award.

'Chilling . . . Reads like a West Coast version of All the President’s Men.' New York Times Book Review

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.

In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Now to be adapted into a film, with Jennifer Lawrence to star.

High technology--which accounts for a rapidly growing section of the global workforce--presents a different set of management problems than have usually been encountered by traditional industry. In this book, Von Glinow, Mohrman, and their expert contributors discuss the reasons for this difference and define new organizational forms for global high technology management. Propounding a revolutionary approach to high technology management issues, they explore management teams, high velocity environments, and high technology marketing, as well as human resource considerations, including team interdependence, compensation, and culture clash.

Master the design and operation of perfusion cell cultures with this authoritative reference. Discover the current state-of-the-art in the design and operation of continuous bioreactors, with emphasis on mammalian cell cultures for producing therapeutic proteins. Topics include the current market for recombinant therapeutic proteins, current industry challenges and the potential contribution of continuous manufacturing. Provides coverage of every step of process development and reactor operation, including small scale screening to lab-scale and scale-up to manufacturing scale. Illustrated through real-life case studies, this is a perfect resource for groups active in the cell culture field, as well as graduate students in areas such as chemical engineering, biotechnology, chemistry and biology, and to those in the pharmaceutical industry, particularly biopharma, biotechnology and food or agro industry.

What do CERN, smartphones, the iridium satellite network, the most popular app stores in the world, the biggest online game in the world, Moscow drivers, Seniors golfer Tony Johnstone, sufferers of rheumatoid arthritis and anyone who has their DNA sequenced have in common? They all rely on innovations that have come out of the technology cluster known as the Cambridge Phenomenon. This book, a follow-up to The Cambridge Phenomenon: 50 Years of Innovation and Enterprise, showcases what the Cambridge technology cluster has done for the world. The Cambridge Phenomenon: Global Impact reveals just how many of us, all around the globe, rely on Cambridge technology every day. This book tells the important, hidden story of how academic excellence and entrepreneurial endeavour have improved people's lives the world over. It is crucial reading for anybody interested in the ways successful businesses work, and the fundamental role of our great educational institutions in fostering that success.

The Silicon phenomenon was, is, and will be an extremely important phenomenon in the accelerated technological, scientific, and economic development of countries and regions. Silicon Valley North (SVN) is the high tech capital of Canada, the nation??'s most developed and dynamic technology sector, which includes multiple clusters in telecommunications, software, photonics, and life sciences. It gave birth to many well-known companies such as Corel, JDS Uniphase, Mitel, Newbridge Networks, Nortel Networks, Digital Equipment of Canada, just to mention a few. A lot of literature describes Silicon Valley and Silicon Alley in the US, Silicon Islands in Asia, and so on. Despite the quite evident importance of Silicon Valley North for the regional, national, and international technological development (especially when Nortel Networks and JDS Uniphase became global leaders in their fields and expanded in explosive fashion), this phenomenon is far from being well understood. Because of this, a book on the Canadian Silicon Valley is an exceptionally timely endeavor.
Silicon Valley North: A High-Tech Cluster of Innovation and Entrepreneurship is devoted to the multidimensional and multifaceted nature of SVN, its history, current state and future developments. The book offers a broad and deeply thematic analysis of one particular innovative cluster???Silicon Valley North. The reader will obtain expert insight into what SVN is all about by acquiring a comprehensive and "panoramic picture" of SVN within a single book. The reader will develop an accurate sense of what spurs high tech start-up companies in SVN toward their exceptional performances, and how to apply these insights to his or herunique regional context.

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

This is a full-length history of the Western Electric Company, which was the manufacturing arm of the Bell System. As manufacturer in the communications revolutions in the nineteenth and twentieth centuries, Western Electric made products that accelerated society's pace, such as telegraphs, telephones, an early computing machine, radios, radar and transistors. Western's history offers numerous examples of the difference between innovation and implementation. The aftermath of Western's 1882 acquisition by Bell Telephone, for instance, reveals vertical integration as a lengthy process rather than a single event. Ironically, although Western transformed business worldwide with innovations in areas such as quality control and industrial psychology, the company was slow to implement these innovations itself. Western's dual role as captive supplier for a regulated monopoly and as government contractor led to its most rapid change, in the area of civil rights.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history.

This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits.

This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

"Sony vs. Samsung" is business history at its best! It explores the divergent fortunes of these two electronics giants in the last decade and identifies the true reasons behind Sony's decline and Samsung's rise. Contrary to popular belief, Chang shows that success (or failure) does not simply arise from different strategies. Rather, it emerges from major decisions that are deeply rooted in the companies' organizational processes and their executives' political behavior. This book is a must-read for any senior executive. --Constantinos Markides
"Robert P. Bauman Professor of Strategic Leadership and Chairman,
Strategy Department, London Business School"

Sea-Jin Chang has produced that rarity in a business book--one that is as valuable to practicing managers as it is insightful to academic researchers. In this fascinating comparison of two modern global giants, he applies his high resolution research microscope to their changing fortunes by dissecting their contrasting strategies, and providing interesting insights into their divergent organizational processes and management practices. This is a very valuable contribution to the international business literature. It will end up in as many corporate boardrooms as faculty seminars.--Christopher A. Bartlett
"Thomas D. Casserly Professor Emeritus, Harvard Business School"

Sea-Jin Chang has written a fascinating comparison of Sony and Samsung that will be valuable to anyone interested in strategy, organizations or international business. The interwoven and very detailed case studies of two very different companies in overlapping industries illuminate problems such as adaptation to technological change (analog to digital), organizational flexibility and globalization. His attempt to analyze both strategic development and implementation is successful and very useful. Both academics and practitioners will learn a lot from this book.--Stephen J. Kobrin, "William Wurster Professor of Multinational Management, The Wharton School, University of Pennsylvania"

Refreshingly original and entertaining, this book analyzes major strategic decisions of Samsung and Sony and highlights organizational processes and top management leadership that have shaped their performances. This is a must-read for all executives who want to understand the strengths and weaknesses of Asian competitors. It also provides penetrating insights to other Asian companies with global ambitions.-- Myoung Woo Lee, "President and CEO
iriver"

Digital Innovation for Healthcare in COVID-19 Pandemic: Strategies and Solutions provides comprehensive knowledge and insights on the application of information technologies in the healthcare sector, sharing experiences from leading researchers and academics from around the world. The book presents innovative ideas, solutions and examples to deal with one of the major challenges of the world, a global problem with health, economic and political dimensions. Advanced information technologies can play a key role in solving problems generated by the COVID-19 outbreak. The book addresses how science, technology and innovation can provide advances and solutions to new global health challenges. This is a valuable resource for researchers, clinicians, healthcare workers, policymakers and members of the biomedical field who are interested in learning how digital technologies can help us avoid and solve global disease dissemination.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history. This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits. This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

This book integrates a science and business approach to provide an introduction and an insider view of intellectual property issues within the biotech industry, with case studies and examples from developing economy markets. Broad in scope, this book covers key principles in pharmaceutical, industrial, and agricultural biotechnology within four parts. Part 1 details the principles of intellectual property and biotechnology. Part 2 covers plant biotechnology, including biotic and abiotic stress tolerance, GM foods in sustainable agriculture, microbial biodiversity and bioprospecting for improving crop health and productivity, and production and regulatory requirements of biopesticides and biofertilizers. The third part describes recent advances in industrial biotechnology, such as DNA patenting, and commercial viability of the CRISPR/Cas9 system in genome editing. The final part describes intellectual property issues in drug discovery and development of personalized medicine, and vaccines in biodefence. This book is an ideal resource for all postgraduates and researchers working in any branch of biotechnology that requires an overview of the recent developments of intellectual property frameworks in the biotech sector.

The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.

Governments around the world have policies to promote links between industry and academic and government laboratories in order to foster economic growth and innovation in the technology-based industries. Knowledge Frontiers gives new insights into this process and offers an original framework for tracking these interactions. The book shows what 'knowledge' companies want from public sector research, and how they network to get this knowledge in three new and promising fields of advanced technology - biotechnology, engineering ceramics, and parallel computing. The authors first look at some of the background issues - policy issues about links between industry and public sector research; the ways in which science and technology interact in the innovation process; and general developments in each of the technologies examined. They look in more detail at public-private research links in the three areas. They find similarities which point to the general importance to innovation of frontier research in universities, and the need to encourage informal interaction/contact between industrial and public sector researchers. They also find differences between the fields which suggest that the policies to provide research links should be more effectively targeted, as an integral part of the broader objective of fostering 'strategic technologies'. Knowledge Frontiers advances our understanding of the various types of knowledge used in the course of research, design, and development leading to innovation. It is essential reading for those wanting to get to grips with the complex and dynamic realities of the innovation process - be they researchers, managers, or policy makers.